Skip to content
Home/Companies/Biotech/Brink Therapeutics
Brink Therapeutics

Brink Therapeutics

Biotech·France·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Brink Therapeutics?

Brink Therapeutics is a French Biotech company, currently owned by Breega since 2025.

Hand-verified · updated 2026-05-07

Open JSON · CC-BY
Breega
Investor
Breega
Breega Seed fund · 2023 · VC

Key facts

HQFrance
SectorBiotech
StatusActive
Websitewww.brinktx.com

More from Breega Seed fund

Other portfolio companies in the same fund.

BioOrbit
BioOrbit
Active
BiotechUK· 2026
Keith
Keith
Active
LegalTechUK· 2026
Quideos
Active
FintechFrance· 2026
Edailabs
Active
EdTechFrance· 2025
Ensol
Active
ClimateTechFrance· 2025
Flow48
Flow48
Active
FintechUAE· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Brink Therapeutics?

Brink Therapeutics is currently owned by Breega, through Breega Seed fund, since 2025.

When did Breega acquire Brink Therapeutics?

Breega acquired Brink Therapeutics in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue